NCT01190826

Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma

Single-Center, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of a Single Dose of ASM-024 Administered by Inhalation to Subjects With Stable Moderate Asthma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Asmacure Ltée · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and clinical activity of ASM-024 in stable moderate asthma.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	ASM-024	Target dose of 10 mg ASM-024 administered once by inhalation
DRUG	ASM-024 100 mg	Target dose of 100 mg ASM-024 administered once by inhalation
DRUG	Placebo	Placebo administered once by inhalation

Timeline

• Start date: 2010-08-01
• Primary completion: 2011-12-01
• Completion: 2012-02-01
• First posted: 2010-08-30
• Last updated: 2012-03-15

Locations

3 sites across 1 country: Canada